About Verenium (NASDAQ:VRNM)
Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Verenium (NASDAQ:VRNM) Frequently Asked Questions
What is Verenium's stock symbol?
Verenium trades on the NASDAQ under the ticker symbol "VRNM."
Who are some of Verenium's key competitors?
Some companies that are related to Verenium include Second Sight Medical (EYES), HopFed Bancorp (HFBC), Forward Pharma (FWP), Columbia Laboratories (JNP), Transglobe Energy (TGA), Aileron Therapeutics (ALRN), ConforMIS (CFMS), Curis (CRIS), Sunesis Pharmaceuticals (SNSS), Covisint (COVS), HTG Molecular Diagnostics (HTGM), A-Mark Precious Metals (AMRK), Flex Pharma (FLKS), Agile Therapeutics (AGRX), Great Elm Capital (GECC), The Joint (JYNT), Ekso Bionics (EKSO) and Fuel Systems Solutions (FSYS).
Who are Verenium's key executives?
Verenium's management team includes the folowing people:
- James H. Cavanaugh Ph.D., Independent Chairman of the Board (Age 77)
- James E. Levine, President, Chief Executive Officer, Director (Age 43)
- Jeffrey G. Black, Chief Financial Officer, Senior Vice President (Age 48)
- Janet S. Roemer, Chief Operating Officer, Executive Vice President - Specialty Enzymes Business Unit (Age 57)
- Alexander A. Fitzpatrick, Senior Vice President, General Counsel, Secretary (Age 47)
- John F. Dee, Independent Director (Age 56)
- Peter R Johnson, Independent Director (Age 61)
- Fernand J. Kaufmann, Independent Director (Age 70)
- Holger A. Liepmann, Independent Director (Age 63)
- Joshua Ruch, Independent Director
Has Verenium been receiving favorable news coverage?
News headlines about VRNM stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Verenium earned a media sentiment score of 0.11 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 44.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Verenium?
Shares of VRNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Verenium's stock price today?
One share of VRNM stock can currently be purchased for approximately $3.99.
How big of a company is Verenium?
Verenium has a market capitalization of $51.01 million.
How can I contact Verenium?
Verenium's mailing address is 3550 John Hopkins Ct, SAN DIEGO, CA 92121-1121, United States. The biotechnology company can be reached via phone at +1-858-4318500.
MarketBeat Community Rating for Verenium (VRNM)MarketBeat's community ratings are surveys of what our community members think about Verenium and other stocks. Vote "Outperform" if you believe VRNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Verenium (NASDAQ:VRNM) Analyst Ratings History
(Data available from 4/21/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Verenium (NASDAQ:VRNM) Earnings History and Estimates Chart
Verenium (NASDAQ VRNM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2013||Q2 2013||($0.32)||($0.36)||$15.70 million||$15.39 million||View||N/A|
|5/9/2013||Q1 2013||($0.27)||($0.47)||$13.79 million||View||N/A|
|3/27/2013||Q4 2012||($0.29)||($0.28)||$14.32 million||$13.98 million||View||N/A|
|11/8/2012||Q312||($0.41)||$18.42 million||$10.26 million||View||N/A|
Verenium (NASDAQ:VRNM) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Verenium (NASDAQ VRNM) News Headlines
Verenium (NASDAQ:VRNM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Verenium (NASDAQ:VRNM) Income Statement, Balance Sheet and Cash Flow Statement
Verenium (NASDAQ VRNM) Stock Chart for Saturday, April, 21, 2018